… ProQR In-licenses Worldwide Rights to Ophthalmology Drug … said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have … will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through …
… ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten … für die Augenheilkunde von Ionis Pharmaceuticals ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5 … LEIDEN (Niederlande), Oct. 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), ein Unternehmen, das …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR Therapeutics to Host Virtual Analyst and Investor Event … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Program and member of the Scientific Advisory Board at ProQR. Prof. Gideon Hirschfield, MA(Oxon) MB BChir (Cantab) …
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
… ProQR Announces Presentation on its Axiomer™ RNA Editing … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Development” This presentation will provide an overview of ProQR’s proprietary ADAR-mediated Axiomer RNA editing …